FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR	ROVAL						
OMB Number: 3235-02							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				-												
1. Name and Address of Reporting Person* White Christine Anna					2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [MEIP]						Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O MEI PHARMA, INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/05/2022					\dashv	Officer (give title Other (specify below) below)					
11455 EL CAMINO REAL, SUITE 250				4	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable								olicable			
(Street) SAN DIEGO CA 92130			- "	4. Il Americinent, Date di Original Filed (Montin Day) Tear)							Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)										Person						
		Tab	le I - Non-Dei	ivativ	e Se	curities	s Ac	quired, Di	sposed o	of, or Bei	neficia	lly Owned				
1. Title of Security (Instr. 3) 2. Transa: Date (Month/D				Execution Date,		Code (Ins	ransaction Disposed Of (D) (Instr. 3, 4 5)					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amount	(A) or (D)		Transact (Instr. 3	ion(s)			(
		-	Table II - Deriv (e.g.,					uired, Dis				y Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.54	07/05/2022		A		87,500		(1)	07/05/2032	Common Stock	87,500	\$0.00	87,50	0	D	
Stock Option (Right to Buy)	\$2.95							(2)	07/01/2031	Common Stock	50,000		50,00	0	D	
Stock Option (Right to Buy)	\$1.57							(2)	07/28/2025	Common Stock	20,000		20,00	0	D	
Stock Option (Right to Buy)	\$1.36							(2)	07/29/2026	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$2.83							(2)	07/06/2027	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$4.28							(2)	07/12/2028	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$2.52							(2)	07/01/2029	Common Stock	40,000		40,00	0	D	
Stock Option (Right to Buy)	\$3.49							(2)	07/02/2030	Common Stock	50,000		50,00	0	D	

Explanation of Responses:

- 1. The options will vest in equal monthly installments over twelve months.
- 2. All of such options are presently exercisable.

Remarks:

/s/ Brian G. Drazba, as attorney

07/07/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.									